title: Alterations in platelet function in patients receiving interleukin-6 as cytokine therapy.
abstract: Platelet function in 12 cancer patients was studied sequentially over 97 hr of interleukin-6 (IL-6) daily bolus or continuous infusion (C.I.) therapy. During this period, enhanced ex vivo agonist-induced platelet maximum aggregation (MA) was paralleled by an increase in plasma levels of TXB2 and PF4 as measured by RIA and ELISA, respectively. Platelet-rich plasma (PRP) specimens from bolus IL-6-treated patients demonstrated an increased incorporation of actin-binding protein and myosin in the cytoskeletal core (triton insoluble residue) as shown by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in comparison to control specimens. Similarly, the integrin glycoprotein IIIa (GPIIIa) was also observed to be retained into the cytoskeleton by immunoblot. A significant decrease in hypotonic shock response (HSR) was observed over 87 hr of treatment in IL-6 C.I. patients, whereas in IL-6 bolus patients, a significant increase in HSR occurred immediately after the bolus, which was followed by a significant decrease in HSR after 23 hr. These results suggest that IL-6 alters platelet function in vivo.
authors.affiliation: Department of Oncology, Montefiore Medical Center Hospital, Bronx, NY, USA.
authors.forename: L
authors.initials: L
authors.lastname: Oleksowicz
authors.forename: E
authors.initials: E
authors.lastname: Puszkin
authors.forename: Z
authors.initials: Z
authors.lastname: Mrowiec
authors.forename: R
authors.initials: R
authors.lastname: Isaacs
authors.forename: J P
authors.initials: JP
authors.lastname: Dutcher
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016718:Arachidonic Acid / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D004797:Enzyme-Linked Immunosorbent Assay; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D015850:Interleukin-6 / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007700:Kinetics; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D010974:Platelet Aggregation / Q000187:drug effects*; D010976:Platelet Count / Q000187:drug effects; D010978:Platelet Factor 4 / Q000378:metabolism; D011863:Radioimmunoassay; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D015850:Interleukin-6; D016718:Arachidonic Acid; D010978:Platelet Factor 4; D013929:Thromboxane B2; D000244:Adenosine Diphosphate; D004837:Epinephrine